

BBS-Bioactive Bone Substitutes Oyj: Managers' Transactions - Jarmo Halonen

BBS-Bioactive Bone Substitutes Plc | Company Release | September 23, 2024 at 17:00:00 EEST

BBS-Bioactive Bone Substitutes Oyj: Managers' Transactions - Jarmo Halonen

Person subject to the notification requirement

Name: Jarmo Halonen

Position: Member of the Board/Deputy member

Issuer: BBS-Bioactive Bone Substitutes Oyj

LEI: 743700BYSBP0PCR6N767

Notification type: INITIAL NOTIFICATION

Reference number: 78331/4/6

Transaction date: 2024-09-10

Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)

Instrument type: SHARE

ISIN: FI4000260583

Nature of transaction: SUBSCRIPTION

Transaction details

(1): Volume: 10,876 Unit price: 0.29 EUR

Aggregated transactions (1):

Volume: 10,876 Volume weighted average price: 0.29 EUR

Transaction date: 2024-09-11

Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)

Instrument type: SHARE

ISIN: FI4000260583

Nature of transaction: SUBSCRIPTION

Transaction details

(1): Volume: 12,740 Unit price: 0.29 EUR

Aggregated transactions (1):

Volume: 12,740 Volume weighted average price: 0.29 EUR

For more information, please contact:

Juliusz Rakowski, CEO

+358 50 448 5132

juliusz.rakowski@bbs-artebone.fi

Certified Advisor:

Nordic Certified Adviser AB,

+46 70 551 67 29,

info@certifiedadviser.se

Distribution

Nasdaq Helsinki

<https://www.bbs-artebone.fi/>

BBS in brief

BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi